The Shotlee Journal
Browse Shotlee articles about GLP-1 Medications.
Showing 9 / 937 GLP-1 Medications articles
More Americans are turning to GLP-1 drugs like Wegovy for weight loss, but experts warn of a critical error. The biggest mistake, says obesity specialist Dr. Katherine Saunders, is treating the prescription as the full treatment. Pairing meds with healthy habits amplifies benefits and sustains results.
The VanEck Pharmaceutical ETF (PPH) offers broad pharma exposure but faces headwinds from U.S. drug pricing reforms and heavy Eli Lilly weighting. Down 8% in the past month despite 15% one-year gains, PPH's diversification is tested. Key risks include MFN pricing deals and GLP-1 competition.
India's metabolic therapy market is shifting dramatically after semaglutide's patent expiry, slashing prices by 85-90% and unlocking demand for 75-80 million obese individuals. Ajanta Pharma gears up for generic semaglutide launch, while Sun Pharma leverages innovations for sustained growth. Analysts forecast the GLP-1 segment scaling to INR34-67 billion in 3-5 years amid rising specialist adoption.
In a Phase 2 clinical trial in China, Novo Nordisk's experimental drug UBT251 surpassed Ozempic, achieving greater reductions in blood sugar (up to 2.16% HbA1c drop) and body weight (up to 9.8% loss). This marks a potential advancement for type 2 diabetes management. Patients on semaglutide saw 1.77% HbA1c and 4.8% weight reductions, while placebo groups lagged behind.
Gayle King's dramatic slim-down over the past two years has social media buzzing with Ozempic speculation, especially her facial changes like hollow eyes and sunken cheeks. Plastic surgeon Dr. Michael Omidi breaks down 'Ozempic face' and how to address it. Yet, the CBS star credits Weight Watchers and mindset shifts for her 25-pound loss post-menopause.
Dale, a 38-year-old former army HGV driver, shed pounds on Mounjaro but turned to grey market peptides when prices soared. Inside Discord groups buzzing with rave reviews, he bought unlicensed BPC157 and CJC-1295 with Ipamorelin. This glimpse reveals the booming, risky world of grey market peptide sourcing for weight loss.
Peptides, once a Silicon Valley biohacking secret, are exploding in popularity—search interest now tops Ozempic. With RFK Jr. poised to reverse FDA restrictions, compounding pharmacies and telehealth platforms are racing to supply them legally. This could propel the $52B peptide market to $87B by 2035.
In a strategic move, Novo Nordisk has elected Poul Weihrauch, CEO of Mars, as a board observer to enhance its consumer presence in the competitive US obesity market. This comes alongside new board members and a 2025 leadership overhaul. The appointment underscores efforts to make Wegovy more accessible through telehealth and direct-to-consumer channels.
Hims & Hers Health, Inc. has partnered with Novo Nordisk to bring a broad assortment of FDA-approved GLP-1 medications to eligible customers, including the groundbreaking Wegovy® pill. This collaboration simplifies access with affordable prices, expanded doses, and diverse delivery methods. As the largest global consumer health platform for these approved meds, Hims & Hers is transforming weight management options.
